{
  "ticker": "FOLD",
  "company_name": "Amicus Therapeutics, Inc.",
  "success": true,
  "trials": [
    {
      "nct_id": "NCT02384460",
      "title": "ESSENCE Study: Efficacy and Safety of SD-101 Cream in Participants With Epidermolysis Bullosa",
      "status": "COMPLETED",
      "phase": "PHASE3",
      "condition": "Epidermolysis Bullosa",
      "start_date": "2015-03-11",
      "completion_date": "2017-07-05",
      "enrollment": 0,
      "sponsor": "Scioderm, Inc."
    },
    {
      "nct_id": "NCT02090283",
      "title": "Open-Label Extension Study to Evaluate the Safety of SD-101 Cream in Participants With Epidermolysis Bullosa",
      "status": "TERMINATED",
      "phase": "PHASE2",
      "condition": "Epidermolysis Bullosa",
      "start_date": "2014-03-26",
      "completion_date": "2018-09-14",
      "enrollment": 0,
      "sponsor": "Scioderm, Inc."
    },
    {
      "nct_id": "NCT02014376",
      "title": "Study of Effectiveness and Safety of SD-101 in Participants With Epidermolysis Bullosa",
      "status": "COMPLETED",
      "phase": "PHASE2",
      "condition": "Epidermolysis Bullosa",
      "start_date": "2014-01-06",
      "completion_date": "2014-06-24",
      "enrollment": 0,
      "sponsor": "Scioderm, Inc."
    },
    {
      "nct_id": "NCT02670330",
      "title": "Open Label Extension Study to Evaluate the Long-term Safety of Zorblisa (SD-101-6.0) in Patients With Epidermolysis Bullosa",
      "status": "TERMINATED",
      "phase": "PHASE3",
      "condition": "Epidermolysis Bullosa",
      "start_date": "2015-06-09",
      "completion_date": "2018-09-03",
      "enrollment": 0,
      "sponsor": "Scioderm, Inc."
    },
    {
      "nct_id": "NCT04804566",
      "title": "Understanding Fabry Disease Therapy Choices Through the Eyes of the Patients",
      "status": "COMPLETED",
      "phase": "",
      "condition": "Fabry Disease",
      "start_date": "2023-03-01",
      "completion_date": "2023-11-01",
      "enrollment": 0,
      "sponsor": "Amicus Therapeutics"
    }
  ],
  "summary": {
    "total_trials": 5,
    "by_phase": {
      "PHASE3": 2,
      "PHASE2": 2,
      "": 1
    },
    "by_status": {
      "COMPLETED": 3,
      "TERMINATED": 2
    },
    "active_trials": 0,
    "completed_trials": 3,
    "conditions": [
      "Epidermolysis Bullosa",
      "Fabry Disease"
    ],
    "lead_stage": "phase_3"
  },
  "provenance": {
    "source": "ClinicalTrials.gov API v2",
    "timestamp": "2026-01-12T09:33:37.787967",
    "search_query": "Amicus Therapeutics, Inc.",
    "url": "https://clinicaltrials.gov/search?term=Amicus+Therapeutics,+Inc."
  }
}